Ted Skolarus to Prostate-Specific Antigen
This is a "connection" page, showing publications Ted Skolarus has written about Prostate-Specific Antigen.
Connection Strength
3.315
-
Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy. JNCI Cancer Spectr. 2022 05 02; 6(3).
Score: 0.716
-
Association between PSA values and surveillance quality after prostate cancer surgery. Cancer Med. 2019 12; 8(18):7903-7912.
Score: 0.602
-
The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol. 2007 Nov; 4(11):605-14.
Score: 0.262
-
National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer. Urology. 2024 Feb; 184:135-141.
Score: 0.199
-
Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer. 2023 10 15; 129(20):3326-3333.
Score: 0.194
-
Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer. J Urol. 2022 09; 208(3):600-608.
Score: 0.179
-
Factors influencing treatment of veterans with advanced prostate cancer. Cancer. 2021 07 01; 127(13):2311-2318.
Score: 0.166
-
Characterising potential bone scan overuse amongst men treated with radical prostatectomy. BJU Int. 2019 07; 124(1):55-61.
Score: 0.141
-
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. J Urol. 2018 09; 200(3):541-548.
Score: 0.135
-
Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. J Clin Oncol. 2016 10 10; 34(29):3586-3587.
Score: 0.122
-
Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. Eur Urol. 2016 08; 70(2):209-10.
Score: 0.116
-
Expectant management of veterans with early-stage prostate cancer. Cancer. 2016 Feb 15; 122(4):626-33.
Score: 0.114
-
Reducing PSA-Based Prostate Cancer Screening in Men Aged?75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support. J Gen Intern Med. 2015 Aug; 30(8):1133-9.
Score: 0.109
-
Technology diffusion and diagnostic testing for prostate cancer. J Urol. 2013 Nov; 190(5):1715-20.
Score: 0.096
-
Reconsidering the Trade-offs of Prostate Cancer Screening. N Engl J Med. 2020 09 24; 383(13):1289-1290.
Score: 0.040
-
Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology. 2018 06; 116:68-75.
Score: 0.034
-
Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. J Urol. 2017 09; 198(3):600-607.
Score: 0.031
-
Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. Health Aff (Millwood). 2017 01 01; 36(1):108-115.
Score: 0.031
-
Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6.
Score: 0.029